Drug intelligence / Profile preview

BFB-201

Development stage: Preclinical
Lead developer: BlackfinBio
Modality: Gene Therapies
Administration: Intracerebral (anticipated)

Overview

BFB-201 is a preclinical-stage gene therapy developed by BlackfinBio for the treatment of dopamine deficiency disorders, including Parkinson's disease. The therapy utilizes a three-gene fusion construct (AADC-TH-CH) designed to address multiple dopamine-related neurological diseases. The approach involves gene transference, aiming to restore or enhance dopamine synthesis in affected patients. BlackfinBio acquired relevant intellectual property from OXB and is advancing BFB-201 as part of its pipeline focused on rare neurological conditions[2][5][6].

Targets

DDC (Aromatic L-amino acid decarboxylase)TH (Tyrosine hydroxylase)GCH1 (GTP cyclohydrolase 1)

Beyond the preview

Go deeper on BFB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BFB-201.

Explore the full profile